+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer

Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer

Disease Markers 2015: 435656

MicroRNA-21 was upexpressed in gastric cancer (GC) indicating that it is a potential diagnostic biomarker for GC. In this study, 50 GC patients and 50 healthy controls were recruited. miR-21 levels in serum and peripheral blood mononuclear cells (PBMCs) were quantified using quantitative real-time PCR. CA199, and CEA were measured using electrochemiluminescence assay. The sensitivity and specificity of circulating miR-21, CA199 and CEA in GC diagnosis, the correlation of circulating miR-21 to clinicopathological features, and the diagnostic value of miR-21 in different GC stages were determined. The levels of miR-21 in both serum and PBMCs increased significantly in GC patients comparing to healthy controls; however, no correlation was observed between circulating miR-21 level and clinicopathological features. The sensitivity and specificity of miR-21 in serum and PBMCs, and CA199 and CEA in GC diagnosis were 88.4%, 79.6%, 81.3%, 73.4%, 60.5%, 55.9%, and 68.6%, 59.3%, respectively. The positive prediction rates of circulating miR-21 in GC stages I to IV were all around 90%, while those of CA199 and CEA were around or less than 50%. Our data suggest circulating miR-21 (both in serum and in PBMCs) can serve as a good biomarker for GC and could be used in diagnosis of early (stage I) and late GC (stage IV).

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057409358

Download citation: RISBibTeXText

PMID: 26063956

DOI: 10.1155/2015/435656

Related references

Circulating microRNA-133, microRNA-17 and microRNA-25 in serum and its potential diagnostic value in gastric cancer. Journal of Cellular Biochemistry 2019, 2019

Circulating MicroRNA-26a in Plasma and Its Potential Diagnostic Value in Gastric Cancer. Plos One 11(3): E0151345, 2016

MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. Journal of Surgical Oncology 108(2): 89-92, 2013

Circulating miR-21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker. Journal of Cancer Research and Therapeutics 14(2): 475, 2018

Circulating microRNA-196a is an early gastric cancer biomarker. Oncotarget 9(12): 10317-10323, 2018

Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer. Annals of Oncology 27(10): 1879-1886, 2017

A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer. International Journal of Gynecological Cancer 27(1): 3-10, 2016

Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Science 101(10): 2087-2092, 2010

Circulating Pre-microRNA-488 in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer. Anticancer Research 38(8): 4515-4523, 2018

Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis. Molecules 19(5): 6282-6293, 2014

Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. Journal of Translational Medicine 10: 186, 2013

A two-microRNA signature as a potential biomarker for early gastric cancer. Oncology Letters 7(3): 679-684, 2014

The diagnostic value of circulating microRNAs as a biomarker for gastric cancer: A meta‑analysis. Oncology Reports 41(1): 87-102, 2018

The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. Plos One 8(6): E66842, 2014

Circulating miR-338-5p is a potential diagnostic biomarker in colorectal cancer. Journal of Digestive Diseases 19(7): 404-410, 2018